

RECEPTOR BINDING OF FUNGAL CELL WALL (1 \rightarrow 3)- β -D-GLUCAN TO HUMAN MACROPHAGE AND NEUTROPHIL CELL LINES

David L. Williams¹, Antje Mueller¹, John Raptis¹,
Peter Rice² and John Kalbfleisch³

Departments of Surgery¹, Pharmacology²
and Medical Education³

James H. Quillen College of Medicine
East Tennessee State University
Johnson City, TN

Abstract

Herein, we will review the evidence for the binding of fungal derived (1 \rightarrow 3)- β -D-glucans to receptors on human macrophage U937 and neutrophil HL-60 cell lines. We have observed binding of yeast derived (1 \rightarrow 3)- β -D-glucan to multiple receptors in each cell line. We have also demonstrated that the receptor(s) is specific for (1 \rightarrow 3)- β -D-glucan binding, since it will not recognize mannan or dextran, non- β linked polymers. In addition, the receptor(s) show dramatic differences in binding affinity between (1 \rightarrow 3)- β -D-glucans. Scleroglucan a triple helical polymer binds with high affinity (IC₅₀ = 23 nM), while single helical glucans, such as glucan phosphate and laminarin, are bound with lower affinity (IC₅₀ = 24 μ M). Our data indicate that human macrophage and neutrophil cell lines have multiple receptors which specifically bind (1 \rightarrow 3)- β -D-glucans and that the triple helical conformation, molecular weight and polymer charge may be important determinants in receptor ligand interaction.

Introduction

The innate immune system has evolved a complex network of receptors which rapidly identify potentially harmful stimuli based on the carbohydrates expressed by the microorganism (Stahl, Fearon and Locksley). Glucans are (1 \rightarrow 3)- β -D-linked polymers of glucose that are produced as fungal cell wall constituents and are also released into the extracellular milieu (Wang et al., Coen et al.). These glucose polymers can exist as a nonbranched (1 \rightarrow 3)- β -linked backbone or as a (1 \rightarrow 3)- β -linked backbone with (1-6)- β -branches (Ensley et al., Lowman et al.). Glucans have been reported to stimulate immunity and decrease infectious complications in humans (Browder et al., Babineau et al., Babineau et al.) and experimental animals (Williams et al.). However, the underlying cellular and molecular mechanisms by which (1-3)- β -D-glucans induce protection have not been defined. The first step in the modulation of cellular activity by (1-3)- β -D-glucans is thought to involve binding to a specific receptor (Mueller et al., Battle et al.). We (Mueller et al., Battle et al.) and others (Thornton et al., Vetrivicka et al., Vetrivicka et al.) have reported receptor

binding of (1 \rightarrow 3)- β -D-glucans in both murine (J774a.1) and human cell lines. Similar results were obtained in both systems. Recent data also indicate that binding of glucans to macrophage and neutrophil cell lines will stimulate the activation and nuclear binding activity of nuclear factor-kappaB (NF κ B) and nuclear factor interleukin 6 (NF-IL6) which may explain, in part, the immunomodulatory activity of these natural product receptor ligands (Adams et al., Battle et al.). This report reviews the evidence for binding/internalization of (1 \rightarrow 3)- β -D-glucan in human macrophage and neutrophil cell lines.

Materials and Methods

Human Cell Lines

We used the human promonocytic cell line U937 and the human neutrophil cell line HL-60. The cells are maintained in RPMI-1640 medium with 10% serum protein supplement at 37°C and 5% CO₂ tension.

Carbohydrate Polymers

Glucan phosphate and glucan sulfate were prepared from water insoluble (1 \rightarrow 3)- β -D-glucan, isolated from *S. cerevisiae* as previously described (Williams et al.). Laminarin and Mannan were purchased from Sigma Chemical Co. (St. Louis, MO). Water soluble scleroglucan was prepared according to the protocol of Pretus et al. Schizophyllan (SPG, derived from *S. commune*) was obtained in sterile water (10 mg/ml) from Kaken Chemical Co. (Tokyo, Japan). Dextran was obtained from Pharmacia (Piscataway, NJ). The primary structure of each carbohydrate polymer was confirmed by variable temperature FT-¹³C-n.m.r. in DMSO-*d*₆ at a concentration of 50 mg/ml as previously described (Ensley et al., Lowman et al.). For the competitive displacement studies, stock solutions of the polysaccharides were prepared in RPMI 1640 cell culture media, filtered and subsequently diluted over a concentration range.

Radiolabeling of a Water Soluble

(1-3)- β -D-Glucan Phosphate

Water soluble (1-3)- β -D-glucan phosphate was radiolabeled as previously described by our group (Mueller et al.). Briefly, ~ 100 mg (1-3)- β -D-glucan phosphate was dissolved in 1.5 ml DMSO overnight at 45°C. This solution is added to a vial containing tritiated NaB₃H₄ (ICN Biomedicals Inc., Irvine, CA; 25 mCi; 718 mCi/mmol). Since the tritium was introduced by reduction of the reducing terminus of the glucan phosphate polymer, a maximum of one tritium per glucan phosphate polymer was introduced.

Receptor-Binding Assays

Receptor binding was evaluated using the Millipore Multiscreen Assay System with 96-well-GF/C glass fibre filter plates (Millipore Corp., Bedford, MA). Displacement binding was determined in the presence of a constant amount of radiolabeled ligand (15 μ g/well) and increasing

concentrations of unlabeled polysaccharide. After incubation at 37°C for 90 minutes the plates were vacuum filtered with subsequent washes (five times with warm serum free RPMI 1640) of the cells. The filters were then harvested and dried, and the radioactivity was determined by liquid scintillation counting (LSC 1409 Wallac Inc., Gaithersburg, MD) with a typical counting efficiency for tritiated glucan phosphate of 45% - 50%.

Data Analysis

Binding displacement data for (1-3)- β -D-glucans were analyzed by nonlinear regression using models of one site competitive displacement (GraphPad Prism, San Diego, CA). Maximum binding was set to that seen in control (labeled glucan phosphate alone) preparations, and displacement set to 100% for polysaccharides without a measurable displacement plateau (*i.e.* glucan phosphate, glucan sulfate, laminarin or scleroglucan). Polysaccharide concentrations displacing 50% of specific binding (IC_{50} values) were determined from the nonlinear regression fits. IC_{50} values of different glucan groups were compared with the least significant difference procedure following a significant F-test in a 1-way ANOVA. $P \leq 0.05$ was considered to be significant.

Results

Competitive Binding Parameters for (1 \rightarrow 3)- β -D-Glucan to U937

Representative competition binding curves are shown in Figure 1. Scleroglucan exhibits the highest binding affinity to the human monocyte (1-3)- β -glucan receptor with a IC_{50} of 23 nM (Fig. 1). This is approximately three orders of magnitude greater than the other carbohydrate polymers. The competitive binding affinities for the carbohydrate polymers were scleroglucan > schizophyllan > laminarin > glucan phosphate > glucan sulfate (Fig. 1). We observed 100 % displacement of the labeled ligand with unlabeled glucan phosphate and schizophyllan. Scleroglucan, laminarin and glucan sulfate also displaced the labeled ligand, but at a lower level (Fig. 1). Dextran and mannan did not compete for binding with the radiolabeled glucan phosphate ligand (data not shown).

Competitive Binding Parameters for (1 \rightarrow 3)- β -D-Glucan to HL-60

Representative competition binding curves are shown in Figure 2. Scleroglucan competed with labeled glucan phosphate for binding ($K_D=127$ nM). Laminarin, a low molecular weight (7.7×10^3 g/Mol) neutral (1 \rightarrow 3)- β -D-glucan also competed for binding, but showed two binding sites ($K_D=2$ μ M and >1 mM). Non- β -linked polymers such as dextran and mannan did not compete for binding in any of these studies (data not shown).

Discussion

The data presented demonstrates not only the specificity of the macrophage U937 and neutrophil HL-60 receptor(s) for (1 \rightarrow 3)- β -D-glucans, but also its ability to differentiate between (1 \rightarrow 3)- β -D-glucans. In this study non β -D-linked carbohydrate polymers did not bind to the U937 or HL-60 cell lines (*i.e.* mannan and dextran). We have previously reported that pullulan, a (1-4)- α -linked glucose polymer did not compete for binding to the U937 glucan receptor (Mueller et al.). Within the group of (1 \rightarrow 3)- β -D-glucan polymers examined, the receptor showed differential affinity, which appeared to be based primarily on solution conformation and to a lesser extent molecular weight and polymer charge. We speculate that the rigid solution conformation (triple helix) is of greater importance in receptor recognition of the polymer because the more highly ordered (*i.e.* rigid) triple helical glucan structure is the predominant form found in the cell wall of most fungi (Cabib et al., Elorza et al., Kapteyn et al.).

Glucan sulfate and glucan phosphate are polyelectrolyte (1 \rightarrow 3)- β -D-glucans (Williams et al., Williams et al.). Laminarin, schizophyllan and scleroglucan are neutral polysaccharides (Pretus et al., Mueller et al., Williams et al.). Laminarin, schizophyllan and scleroglucan exhibit varying degrees of (1 \rightarrow 6)- β side chain branching (Pretus et al., Williams et al.). Even though we were dealing with a small number of well characterized polymers there were several distinct observations that emerged. Glucan sulfate and glucan phosphate showed significantly lower binding affinities than did the neutral polysaccharides, laminarin, schizophyllan and scleroglucan. This suggests that the presence of the charged species on the polymer may alter binding affinity. All of the neutral polysaccharides exhibited branching frequencies that were greater than the polyelectrolyte glucans. In general, the receptor showed significantly greater affinity for the branched neutral polysaccharides. Schizophyllan and scleroglucan are similar in that both of these polymers have a branching frequency of approximately 1 branch per every third glucose subunit along the (1 \rightarrow 3)- β -D-linked polymer backbone (Pretus et al.). A number of reports suggest the bioactivity of (1 \rightarrow 3)- β -D-glucans is related to the degree of side chain branching (Chiba et al., Kiho et al., Kurachi et al., Nemoto et al., Suzuki et al.). However, we observed dramatic differences between the binding affinity of schizophyllan ($IC_{50} = 11$ μ M) and scleroglucan ($IC_{50} = 23$ nM) even though their branching frequency was very similar. When we compared the binding affinity of laminarin (1:10 branching) versus schizophyllan (1:3 branching) we observed a modest (21 μ M vs. 11 μ M), but significant difference. Thus, we conclude that branching frequency may enhance the affinity of the polymer for the U937 glucan receptor. We also noted that the polymers with the greatest molecular weight (*i.e.* schizophyllan and scleroglucan) exhibited higher binding affinities. Kojima et al. have reported that the anti-tumor activity of

schizophyllan is molecular weight dependent. This may reflect differences in pharmacokinetics rather than binding affinity. In our study the contribution of molecular weight cannot solely account for the differences since the binding affinity of schizophyllan was 11 μ M and scleroglucan was 23 nM. By far the most significant difference in binding affinity appeared to strongly correlate with solution conformation. Solution conformation refers to the tertiary structure which the polymer assumes in the aqueous environment. In this study we examined the solution conformation by establishing the linear scaling relationships for each glucan using the methods described by Mueller et al. We found that scleroglucan was unique in that it had a highly ordered solution conformation. This indicates that scleroglucan exists predominantly in solution as a rigid triple helix as compared to the other glucans which show scaling relationships that suggest a single helical solution conformation which would resemble a semi-flexible or perturbed coil (Mueller et al.). Thus, the dramatic difference between the binding affinity of the receptor for scleroglucan seems to involve the more rigid solution structure. However, we cannot discount the effects of molecular mass on this polymer system.

The studies of Muller, Battle, Thornton, Duan, Zimmerman, Dushkin, Vetvicka and colleagues suggest that there are multiple (1 \rightarrow 3)- β -D-glucan binding sites on macrophages and neutrophils. The data presented confirm and extend this observation by demonstrating that schizophyllan and glucan phosphate can completely displace the binding of labeled glucan phosphate. However, glucan sulfate, laminarin and scleroglucan can only displace a portion of the labeled glucan phosphate. By way of example, the receptor affinity for glucan sulfate and scleroglucan is significantly different, but both of the ligands can only displace ~40% of the labeled glucan phosphate. In U937 cells laminarin can displace ~60% of glucan phosphate binding. We speculate that there are at least two binding sites on U937, both of which recognize and bind schizophyllan and glucan phosphate. However, scleroglucan and glucan sulfate interact with only one of the sites, while laminarin interacts with the other. The HL-60 data clearly show that laminarin competition fits a two site binding curve, while scleroglucan competition fits a one site binding curve. Taken together these data clearly demonstrate the existence of at least two binding sites for (1 \rightarrow 3)- β -D-glucan on U937 and HL-60.

Acknowledgements

This study was supported in part by NIH RO153522 to DLW.

References

- Adams, D.S., Pero, S.C., Petro, J.B., Nathans, R., Mackin, W.M., and Wakshull, E. 1997. PGG-Glucan activates NF-kB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. *Journal of Leukocyte Biology*. 865-873.
- Babineau, T.J., Hackford, A., Kenler, A., Bistrrian, B., Forse, R.A., Fairchild, P.G., Heard, S., Keroack, M., Causha, P., and Benotti, P. 1994. A Phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (pgg-glucan) in high-risk surgical patients. *Arch.of Surgery*. 1204-1210.
- Babineau, T.J., Marcello, P., Swails, W., Kenler, A., Bistrrian, B., and Forse, R.A. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. *Annals of Surgery*. 601-609.
- Battle, J., Ha, T., Li, C., Della Beffa, V., Rice, P., Kalbfleisch, J., Browder, W., and Williams D. 1998. Ligand binding to the (1 \rightarrow 3)-beta-D-glucan receptor stimulates NFkB activation, but not apoptosis in U937 cells. *Biochemical and Biophysical Research Communications*. 499-504.
- Browder, W., Williams, D., Pretus, H., Olivero, G., Enrichens, F., Mao, P., and Franchello, A. 1990. Beneficial effect of enhanced macrophage function in the trauma patient. *Annals of Surgery*. 605-613.
- Cabib, E., Mol, P.C., Shaw, J.A., and Choi, W.J. 1993. Biosynthesis of cell wall and septum during yeast growth. *Arch.Med.Res*. 301-303.
- Chiba, N., Ohno, N., Terui, T., Adachi, Y., and Yadomae, T. 1996. Effect of highly branched (1 \rightarrow 3)-b-D-glucan, OL-2, on zymosan-mediated hydrogen peroxide production by murine peritoneal macrophages. *Pharmaceutical and Pharmacological Letters*. 12-15.
- Coen, M.L., Lerner, C.G., and Capobianco, J.O. 1995. Synthesis of yeast cell wall glucan and evidence for glucan metabolism in a *Saccharomyces crevisiae* whole cell system. *Microbiology*. 2229-2237.
- Duan, X., Ackerly, M., Vivier, E., and Anderson, P. 1994. Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function. *Cell Immunol*. 393-402.

- Dushkin, M.I., Safina, A.F., Vereschagin, E.I., and Schwartz, Y.S. 1996. Carboxymethylated beta-1,3-glucan inhibits the binding and degradation of acetylated low density lipoproteins in macrophages in vitro and modulates their plasma clearance in vivo. *Cell Biochem.Funct.* 185-215.
- Elorza, M.V., Garcia de la Cruz, F., San Juan, R., Marcilla, A., Rico, H., Mormeneo, S., and Sentandreu, R. 1993. Linkages between macromolecules in *Candida albicans* cell wall. *Arch.Med.Res.* 305-310.
- Ensley, H.E., Tobias, B., Pretus, H.A., McNamee, R.B., Jones, E.L., Browder, I.W., and Williams, D.L. 1994. NMR spectral analysis of a water-insoluble (1-3)-b-d-glucan isolated from *Saccharomyces cerevisiae*. *Carbohydrate Research.* 307-311.
- Fearon, D.T. and Locksley, R.M. 1996. The instructive role of innate immunity in the acquired immune response. *Science.* 50-53.
- Kapteyn, J.C., Montijn, R.C., Dijkgraaf, G.J.P., Van den Ende, H., and Klis, F.M. 1995. Covalent association of b-1, 3-Glucan with b-1, 1-6 glucosylated mannoproteins in cell walls of *Candida albicans*. *J of Bacteriology.* 3788-3792.
- Kiho, T., Katsuragawa, M., Nagai, K., and Ukai, S. 1992. Structure and antitumor activity of a branched (1-3)-b-D-glucan from the alkaline extract of *Amanita Muscaria*. *Carbohydrate Research.* 237-243.
- Kojima, T., Tabata, K., Itoh, W., and Yanaki, T. 1986. Molecular weight dependence of the antitumor activity of Schizophyllan. *Argic.Biol.Chem.* 231-232.
- Kurachi, K., Ohno, N., and Yadomae, T. 1990. Preparation and antitumor activity of hydroxyethylated derivatives of 6-branched (1 \rightarrow 3)-beta-D-glucan, SSG, obtained from the culture filtrate of *Sclerotinia sclerotiorum* IFO 9395. *Chem.Pharm.Bull.Tokyo.* 2527-2531.
- Lowman, D., Ensley, H., and Williams, D. 1998. Identification of phosphate substitution sites by NMR spectroscopy in a water-soluble phosphorylated (1-3)-b-D-glucan. *Carbohydr Res.* 559-562.
- Mueller, A., Pretus, H., McNamee, R., Jones, E., Browder, I., and Williams, D. 1995. Comparison of the carbohydrate biological response modifiers Krestin, schizophyllan and glucan phosphate by aqueous size exclusion chromatography with in-line argon-ion multi-angle laser light scattering photometry and differential viscometry detectors. *Journal of Chromatography.* 283-290.
- Mueller, A., Rice, P.J., Ensley, H.E., Coogan, P.S., Kalbfleisch, J.H., Kelley, J.L., Love, E.J., Portera, C.A., Ha, T., Browder, I.W., and Williams, D.L. 1996. Receptor binding and internalization of water-soluble (1 \rightarrow 3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines. *Journal of Immunology.* 3418-3425.
- Nemoto, J., Ohno, N., Saito, K., Adachi, Y., and Yadomae, T. 1993. Expression of interleukin 1 family mRNAs by a highly branched (1 \rightarrow 3)-beta-D-glucan, OL-2. *Biol.Pharm.Bull.* 1046-1050.
- Pretus, H.A., Ensley, H.E., McNamee, R.B., Jones, E.L., Browder, I.W., and Williams, D.L. 1991. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. *Journal of Pharmacology and Experimental Therapeutics.* 500-510.
- Stahl, P.D. 1992. The mannose receptor and other macrophage lectins. *Current Opinion in Immunology.* 49-52.
- Suzuki, I., Hashimoto, K., and Yadomae, T. 1988. The effects of a highly branched beta-1,3-glucan, SSG, obtained from *Sclerotinia sclerotiorum* IFO 9395 on the growth of syngeneic tumors in mice. *J.Pharmacobiodyn.* 527-532.
- Thornton, B.P., Vetvicka, V., Pitman, M., Goldman, R.C., and Ross, G.D. 1996. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). *The Journal of Immunology.* 1235-1246.
- Vetvicka, V., Thornton, B.P., and Ross, G.D. 1996. Soluble Beta-Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells. *Journal of Clinical Investigation.* 50-61.
- Vetvicka, V., Thornton, B.P., Wieman, J., and Ross, G.D. 1997. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3. *J Immunol.* 599-605.
- Wang, Y.C. and McNeil, B. 1996. Scleroglucan. *Crit.Rev.Biotechnol.* 185-215.

Williams, D.L., McNamee, R.B., Jones, E.L., Pretus, H.A., Ensley, H.E., Browder, I.W., and Di Luzio, N.R. 1991. A method for the solubilization of a (1-3)- β -D-glucan isolated from *Saccharomyces cerevisiae*. *Carbohydrate Research*. 203-213.

Williams, D.L., Mueller, A., and Browder, W. 1996. Glucan-based macrophage stimulators: A review of their anti-infective potential. *Clin.Immunother.* 392-399.

Williams, D.L., Pretus, H.A., McNamee, R.B., Jones, E.L., Ensley, H.E., Browder, I.W., and Di Luzio, N.R. 1991. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from *Saccharomyces cerevisiae*. *Immunopharmacology*. 139-156.

Zimmerman, J.W., Lindermath, J., Fish, P.A., Palace, G.P., Stevenson, T.T., and DeMong, D.E. 1998. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. *J Biol Chem*. 22014-22020.




Figure 1. Competitive displacement of ^3H -glucan phosphate in U937 cells by unlabeled (1-3)- β -D-glucans.




Figure 2. Competitive displacement of ^3H -glucan phosphate in human HL-60 neutrophil cell line by unlabeled scleroglucan and laminarin.